# Arrowhead Pharmaceuticals (ARWR)

**Exchange:**   
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-10  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/ARWR/primer

## Business Model

---
source: coverage-next-full
ticker: ARWR
step: 01
title: Business Model & Overview
date: 2026-06-09
---

### Step 01 — Business Model & Overview: Arrowhead Pharmaceuticals (ARWR)

#### 1. Executive Summary

Arrowhead Pharmaceuticals is a clinical-stage/early-commercial biopharmaceutical company that develops targeted RNA interference (RNAi) therapeutics using its proprietary TRiM™ (Targeted RNAi Molecule) platform. The company transitioned from a pure research/licensing revenue model to a commercial-stage company on November 18, 2025 when plozasiran (REDEMPLO) received FDA approval for familial chylomicronemia syndrome (FCS). [S1]

The business model has two intertwined value streams: (1) **platform licensing** — monetizing TRiM through large upfront deals with Sarepta Therapeutics, Novartis, Takeda, GSK, and Amgen; and (2) **proprietary commercial products** — building direct product revenue starting with REDEMPLO. These streams are structurally different: licensing creates large, episodic cash inflows that mask the underlying cost burn, while product revenue will grow more slowly but create a durable, recurring revenue base.

---

#### 2. Technology Platform: TRiM™

**What it is:** TRiM (Targeted RNAi Molecule) is Arrowhead's modular siRNA delivery platform. It consists of three linked components: [S1]
1. **Targeting ligand** — routes the drug to a specific cell type (e.g., GalNAc for liver hepatocytes, proprietary ligands for lung epithelium, neurons)
2. **Linker** — connects targeting ligand to payload; enables tissue specificity tuning
3. **siRNA payload** — double-stranded RNA that silences a specific target gene through the endogenous RISC machinery

**How it differs from Alnylam's GalNAc platform:** TRiM is designed to be modular — the targeting ligand can theoretically be swapped to redirect the drug to non-hepatic tissues. This is the basis for Arrowhead's extra-hepatic programs in lung (ARO-RAGE inhaled), CNS (ARO-MAPT, ARO-HTT), and muscle (ARO-DUX4, partnered with Sarepta). Alnylam's GalNAc platform is primarily hepatic; it uses LNP delivery for some non-hepatic programs, which requires IV infusion rather than subcutaneous injection. [S2]

**Subcutaneous delivery:** All TRiM-based programs are delivered via subcutaneous injection, typically quarterly or semi-annually. This is a major commercial advantage vs. IV infusion (reduces hospital visits, increases patient compliance). [S2]

---

#### 3. Value Chain Layer Map

```
Discovery Layer (Internal)
├── Target identification (genetics-validated targets)
├── siRNA sequence optimization
└── TRiM molecule assembly (ligand + linker + siRNA)
          ↓
Development Layer
├── IND-enabling studies / Phase 1 safety
├── Phase 2 proof-of-concept
├── Phase 3 pivotal (PALISADE, SEQUOIA, etc.)
└── Regulatory filing (NDA/BLA with FDA)
          ↓
Commercialization Layer
├── Proprietary (REDEMPLO): Arrowhead-owned US commercial team
│   └── Orphan pricing; KOL-driven FCS market
└── Partnered: Sarepta (rare muscle), Takeda (fazirsiran liver), GSK (HBV/MASH), Amgen (Lp(a))
          ↓
Manufacturing Layer
├── San Diego, CA — research manufacturing
├── Madison, WI — clinical supply
└── Verona, WI — commercial-scale facility (160,000 sq ft, operational 2025)
          ↓
Value Capture
├── Upfront licensing fees (Sarepta $825M, Novartis $200M, etc.)
├── Milestone payments (tied to clinical and commercial events)
├── Royalties (on partner product sales)
└── Direct product revenue (REDEMPLO — FCS launch, sHTG pending)
```

---

#### 4. Revenue Architecture

Arrowhead generates revenue through four mechanisms, with very different risk and timing profiles:

| Revenue Type | Example | Timing | Predictability |
|-------------|---------|--------|---------------|
| Upfront licensing | Sarepta $825M (Q2 FY2025), Novartis $200M (FY2025), GSK $120M (FY2022) | Episodic; deal-closure dependent | Low |
| Clinical milestones | Payments when partner's drug enters Phase 2, 3, etc. | Lumpy; clinical progress dependent | Low-Medium |
| Regulatory/Commercial milestones | NDA submission, FDA approval, first sale | Binary events | Low-Medium |
| Product royalties | Olpasiran (Amgen) royalties sold to Royalty Pharma (2022) | Recurring but Royalty Pharma owns them | N/A for ARWR |
| Direct product revenue | REDEMPLO FCS sales (from Nov 2025) | Recurring; growing slowly | Medium (small market) |

**Structural insight:** The episodic nature of upfront payments creates high revenue volatility — $3.6M in FY2024 vs. $829.4M in FY2025, both legitimate years. The correct way to think about Arrowhead's cash flow is: **underlying R&D burn (~$688M/year) ± large episodic cash inflows from deals**. Product revenue from REDEMPLO will eventually smooth this, but FCS is an ultra-rare disease (~3,000 US patients) so peak product revenue is likely below $100M/year for FCS-only. [S3]

---

#### 5. Business Segments

Arrowhead operates as a single reportable segment (research and development of RNAi therapeutics). The company does not break out revenue by product in detail (it is all collaboration/license revenue under ASC 606). [S1]

**De facto portfolio structure:**
1. **Proprietary commercial assets:** Plozasiran (FCS — launched; sHTG — Phase 3, data Q3 2026); zodasiran (ANGPTL3 — Phase 2/3)
2. **Co-development assets (Takeda):** Fazirsiran (AATD — Phase 3); 50/50 US co-commercialization; 20-25% ex-US royalties
3. **Out-licensed assets (Sarepta):** ARO-DUX4/ARO-MYOD (muscular dystrophy); ARO-LGI1 and others under $825M deal
4. **Out-licensed assets (GSK):** HSD17B13 (MASH, Phase 3); HBV daplusiran (Phase 2)
5. **Out-licensed assets (Amgen):** Olpasiran (Lp(a), Phase 3 — Amgen wholly responsible; royalties sold to Royalty Pharma)
6. **Discovery/early clinical:** ARO-INHBE (obesity/MASH), ARO-RAGE (COPD), ARO-C3 (IgAN), ARO-MAPT (Alzheimer's), ARO-HTT (Huntington's), ARO-SOD1 (ALS)

---

#### 6. Competitive Positioning (Brief)

The RNAi space is oligopolistic. Alnylam holds ~45% market share with 5 approved drugs; ARWR is the newest commercial entrant. Arrowhead's differentiation rests on:
1. **Extra-hepatic delivery** — lung, CNS, muscle programs not replicable with GalNAc alone
2. **Cardiometabolic breadth** — plozasiran (ApoC-III), zodasiran (ANGPTL3), olpasiran (Lp(a) via Amgen), ARO-DIMER (PCSK9+ApoC-III simultaneous)
3. **Platform modularity** — TRiM's ligand-swap architecture enables rapid new program starts
4. **Wisconsin manufacturing facility** — vertical integration reduces reliance on CMOs at scale [S2]

---

#### 7. Key Risks (Overview)

1. **Clinical binary risk:** Phase 3 failure in sHTG (plozasiran PALISADE) would remove the largest commercial opportunity
2. **Balance sheet stress:** $1.37B debt (Q2 FY2026) vs. declining cash reserves after FY2025 windfall
3. **Commercial execution:** First commercial launch with a new team in an ultra-rare disease is notoriously difficult; physicians are unfamiliar with FCS diagnosis
4. **Competition from Alnylam:** Superior commercial infrastructure and scale; potential ANGPTL3 program overlap
5. **R&D spend acceleration:** R&D growing ~20-43% per year with no clear ceiling as pipeline expands

---

#### 8. Source Index

[S1] SEC EDGAR 10-K FY2024 summary — ARWR_financials/sec_filings/10K_FY2024_summary.md
[S2] ARWR Competitive Landscape — ARWR_financials/industry/competitive_landscape.md
[S3] StockAnalysis.com financial summary — ARWR_financials/other/stockanalysis_summary.md
[S4] Consensus and market data — ARWR_financials/other/consensus.md

## Financial Snapshot

---
source: coverage-next-full
ticker: ARWR
step: 04
title: Financial Quality & Adversarial Research Sweep
date: 2026-06-09
---

### Step 04 — Financial Quality & Adversarial Research Sweep: Arrowhead Pharmaceuticals (ARWR)

#### 1. Statement-Quality Assessment

##### Income Statement Quality

**Revenue recognition under ASC 606:**
The single most important quality issue for ARWR's income statement is the episodic, large-lump recognition of collaboration and license revenue. Arrowhead accounts for performance obligations in collaboration agreements and recognizes upfronts over the performance period. [S1]

Key quality issues to note:
- **FY2025 Q2 ($542.7M in one quarter):** The Sarepta deal ($825M+ upfront) creates a one-time revenue spike that is NOT a proxy for run-rate cash generation. Reported FY2025 revenue of $829.4M and operating income of $98.4M are not indicative of sustainable profitability.
- **Deferred revenue dynamics:** Large upfronts create deferred revenue on the balance sheet; as obligations are satisfied, deferred revenue converts to income. This creates a potential GAAP income stream that doesn't correspond to cash received in the same period. At FY2024, deferred revenue from collaborations was ~$103.2M current + $845.6M noncurrent. [S1]
- **R&D expense: all internal R&D is expensed** — no capitalization of drug development costs under US GAAP (they treat FDA approval as the first point where technological feasibility is established). This understates asset value but is standard practice.

**Operating expense quality:**
- R&D expense is the most reliable metric: $607M FY2025, growing ~20% YoY. Breakdowns suggest genuine platform expansion, not padding.
- G&A jumped to $123.9M FY2025 vs. $98.8M FY2024 (+25%) — reflects commercial infrastructure build-up post-plozasiran NDA. G&A as % of R&D is ~20%, reasonable for a company transitioning to commercial stage.
- SBC: declining from $120.9M (FY2022 peak) to $63.4M (FY2025) — positive signal of cost discipline; SBC as % of total revenue was 7.6% in FY2025 vs. inflated in prior years.

**Adjustments recommended:**
1. **Normalize revenue** to deal-adjusted basis: strip out one-time upfronts, focus on milestone cadence and product revenue run-rate
2. **Cash-basis P&L:** Operating cash flow is more informative than GAAP net income for ARWR; FY2025 OCF of $179.6M (positive) vs. FY2024 ($462.9M) (deeply negative)
3. **Exclude non-cash SBC** from EBITDA-like metrics — though SBC is real dilution, it inflates reported OpEx vs. cash burn

##### Balance Sheet Quality

**Total debt build:**
- FY2021: $25.5M (near debt-free)
- FY2022: $81.6M (convertible notes)
- FY2023: $383.5M (Royalty Pharma royalty liability + convertibles)
- FY2024: $851.9M ($400M Sixth Street term loan + Royalty Pharma + convertibles)
- FY2025: $733.7M (some repayment/reclassification)
- Q2 FY2026: $1,373M (major new financing — likely new convertible notes)

**Royalty liability complexity:**
In November 2022, Arrowhead sold its royalty rights on olpasiran (Amgen's Lp(a) drug) to Royalty Pharma for $250M upfront, structured as a **non-recourse royalty purchase** that is classified as debt on Arrowhead's balance sheet under US GAAP. This is a real liability if olpasiran royalties are sufficient to repay it, but it is effectively contingent on Amgen's clinical success. [S1]

**Sixth Street term loan ($400M drawn, Sep 2024):**
- 7-year term, secured by all ARWR assets
- Interest rate ~9–10% (estimated based on prevailing lending terms for clinical-stage biotechs)
- Annual interest expense: ~$36–40M (material cash cost)
- Covenant risk: If clinical programs fail and the company cannot service the debt, this could be a significant distress risk

**Equity quality:**
- Stockholders' equity: $466.1M (FY2025); recovered from near-wipe-out level of $56M in Q1 FY2025
- Book value is largely intangible in practice — most of ARWR's value is in its pipeline IP, not on the balance sheet
- Accumulated deficit at FY2025: Very large (>$2B accumulated losses since inception) — standard for clinical-stage biotech

**Cash quality:**
- FY2025: $88.7M cash + $692.4M short-term investments = $781M liquid
- Q2 FY2026: $147.5M cash (ST investments not separately broken out at Q2 FY2026) — may have been deployed or reclassified
- Q2 FY2026 total assets jumped to $2,268M (from $1,385M at FY2025) — new debt raises likely went to the balance sheet as cash/investments

##### Cash Flow Statement Quality

- **Operating cash flow is the most reliable signal** — it removes deferred revenue and non-cash items
- Q2 FY2026 OCF: $84.4M (positive, suggests Q2 had net cash inflows); Q1 FY2026: $13.5M (positive)
- FY2025 cumulative quarterly OCF: $460M (Q2 FY2025 large receipt) + ($154.7M) + ($146.3M) + $20.5M = $179.5M for the year
- CapEx has normalized to ~$2–8M/quarter in FY2026 after the facility build ($141–177M/year in FY2023–FY2024)

---

#### 2. Adversarial Research Sweep

*Note: No earnings transcripts available on this research path. Adversarial concerns are sourced from SEC filings (10-K risk factors), press coverage, proxy analysis, and insider transaction data.*

##### Issue 1: Say-On-Pay Failure at 2026 Annual Meeting

**What happened:** At the March 19, 2026 Annual Meeting, say-on-pay vote FAILED with 59% of votes cast AGAINST management compensation. 41.6M shares voted FOR, 59.9M shares voted AGAINST — a significant shareholder rebellion. [S3]

**Why it matters:**
- CEO Christopher Anzalone received $9.0M total compensation in FY2025, with $6.8M in RSU grants
- The compensation committee's lead (Michael Perry) received only 69% shareholder support — the lowest of any director
- A new equity plan authorizing 10.5M additional shares was approved (overhang increasing from 5.6% to 11.8% of shares outstanding)
- Say-on-pay failures are rare and signal deep investor dissatisfaction with governance

**Analysis:** The combination of (a) CEO dual role as Chairman + CEO (no independent chair), (b) large equity grants in a year with near-zero product revenue (FY2024 was a trough year), and (c) the 10.5M share equity plan authorization — totaling ~7.5% dilution — appears to have crystalized shareholder frustration.

**Governance red flag severity: MEDIUM-HIGH.** This does not impair the scientific thesis but it signals a management-shareholder alignment problem that could lead to further governance changes, compensation restructuring, or activist involvement.

##### Issue 2: CEO and Insider Selling

**What happened:** CEO Anzalone sold approximately 347,055 shares in December 2025 (~$23.1M at $64–69/share). Multiple directors also sold in the same December 2025 window. Estimated total insider sales over 12 months (Sep 2025–May 2026): $37–40M. [S3]

**Analysis:** December 2025 window (6 weeks post-FDA approval in November 2025) was the first open trading window after the approval catalyst. Selling post-approval is standard for executives who have been holding through the development period and is covered under 10b5-1 plans. However:
- The timing (peak price window) and scale ($23M single executive) is aggressive
- New CFO Daniel Apel (joined May 2025) also sold $934K (April 2026) and filed Form 144 for an additional 100,000 shares
- CEO's sale of 347K shares represents ~0.25% of shares outstanding — not a catastrophic signal but notable

**Red flag severity: MEDIUM.** No insider buying visible. Selling clusters are a caution signal but not a definitive thesis killer.

##### Issue 3: Debt Load and Runway

**What happened:** Total debt rose from near-zero ($25.5M in FY2021) to $1,373M by Q2 FY2026. [S2]

**Components:**
- Royalty Pharma liability (~$250M, related to olpasiran royalty sale — non-recourse per Amgen clinical success)
- Sixth Street term loan ($400M, drawn Sep 2024; 7-year, secured)
- Convertible notes (likely new tranche in Q2 FY2026 given asset jump from $1.4B to $2.3B)

**Cash analysis:**
If Q2 FY2026 total assets jumped $883M ($1,385M → $2,268M) and total debt jumped $639M ($733M → $1,373M), the new debt is likely mostly on the balance sheet as liquid assets (~$640M net inflow). This suggests ARWR raised a large convertible note tranche in Q1 or Q2 FY2026, adding meaningful runway.

Revised liquid assets estimate (Q2 FY2026): ~$147.5M reported cash + ~$640M estimated ST investments from new raise = ~$787M liquid

At ~$215–223M/quarter burn, current liquidity covers approximately 3.5 years without any additional revenue — comfortable for a company with multiple Phase 3 programs expected to read out in 2026–2027.

**Red flag severity: LOW-MEDIUM.** Debt is elevated but appears manageable given large liquid assets and ongoing deal flow. Risk escalates if Phase 3 programs fail and no new deals materialize.

##### Issue 4: R&D Burn Acceleration

**What happened:** Quarterly R&D jumped from $133–137M in early FY2025 to $177M in Q1 FY2026 (+30% YoY). G&A jumped from $26.9M to $46.0M (+71% YoY) in Q1 FY2026 vs. Q1 FY2025. [S2]

**Analysis:** The G&A spike is directly attributable to REDEMPLO commercial infrastructure (commercial team, sales force, patient access programs). R&D acceleration reflects pipeline advancement with 6 Phase 3 programs running simultaneously. Both are "good" spending increases in the context of pipeline/commercial advancement, but they increase the burn rate significantly.

**Red flag severity: LOW.** Accelerating spend is expected; concern would arise only if burn rate exceeds runway.

##### Issue 5: No Product Revenue Track Record

**What happened:** Arrowhead generated no product revenue through FY2024. REDEMPLO launched November 2025.

**Analysis:** The company has never built or operated a commercial infrastructure. FCS is an ultra-rare disease requiring unusual diagnostic steps (patients often go years without a diagnosis). The commercial team is being assembled from scratch. 400+ prescriptions in the first commercial quarter is an early positive signal, but it's too early to conclude commercial execution is proven.

**Red flag severity: MEDIUM.** Commercial execution risk is real but manageable; FCS is a "practice" market for the larger sHTG opportunity.

---

#### 3. Financial Quality Score

| Dimension | Score | Notes |
|-----------|-------|-------|
| Revenue quality | 3/10 | Highly episodic; deal-dependent; not comparable YoY |
| Earnings quality | 3/10 | GAAP earnings completely dominated by deal timing |
| Cash flow quality | 7/10 | OCF is more reliable; normalize for deal receipt timing |
| Balance sheet quality | 5/10 | Assets clean; liabilities complex (Royalty Pharma, term loan, converts) |
| Governance quality | 4/10 | CEO/Chair dual role; say-on-pay failure; aggressive insider selling |
| Disclosure quality | 8/10 | 10-K disclosures are comprehensive; pipeline updates are detailed |

---

#### 4. Source Index

[S1] XBRL Financial Summary + 10-K FY2024 — ARWR_financials/xbrl/ + sec_filings/
[S2] StockAnalysis Financial Summary — ARWR_financials/other/stockanalysis_summary.md
[S3] Governance + Insider Transactions — ARWR_financials/proxy/
[S4] Consensus & News — ARWR_financials/other/consensus.md

## Recent Catalysts

---
source: coverage-next-full
ticker: ARWR
step: 12
title: Bull vs. Bear — Analyst Debate
date: 2026-06-09
---

### Step 12 — Bull vs. Bear: Arrowhead Pharmaceuticals (ARWR)

*Note: Earnings transcripts were not used in this research path. The bull/bear debate is inferred from consensus notes, press releases, filings, and recent news coverage.*

#### 1. Street Consensus Snapshot (June 2026)

- 9 Buy / Strong Buy | 4 Hold | 0 Sell (out of ~13 analysts)
- Average price target: $88.17 (+19.4% upside from $73.86)
- Range: $46 (low) – $110 (Piper Sandler)
- Most recent upgrade: Morgan Stanley → Overweight, $100 PT (April 21, 2026)
- Notable neutral: Goldman Sachs (Neutral; no PT in available data)

The Street is predominantly bullish. The 4 Holds and wide PT range ($46–$110) reflect genuine uncertainty about (a) plozasiran sHTG Phase 3 outcome and (b) long-term revenue model post-milestone-windfall normalization. [S4]

---

#### 2. Bull Case — Core Arguments

##### Bull Argument 1: plozasiran sHTG is a Blockbuster in Waiting
**Bull thesis:** PALISADE/SHASTA-3/MUIR-3 Phase 3 data expected Q3 2026 will be positive, and plozasiran will be approved for severe hypertriglyceridemia — a ~600,000-patient US market with no other FDA-approved drug. At orphan-like pricing (~$150,000–200,000/year) and 10-20% penetration, this is a $1.5–2.5B+ peak annual revenue opportunity. Given REDEMPLO already showed -80% TG reduction in Phase 3 FCS, and the same mechanism applies in sHTG, the probability of success is higher than a typical Phase 3. The market is not fully pricing this in at current valuations.

**Supporting evidence:**
- Phase 3 PALISADE FCS data showed -80% TG reduction at Week 26 — the endpoint was convincingly met
- The sHTG indication uses the same mechanism; only the patient population is broader
- Analysts characterize the sHTG opportunity as a "$4B REDEMPLO opportunity" [S4]
- Competitive moat in sHTG is strong — Waylivra was FDA-rejected; no approved US alternative

##### Bull Argument 2: ARO-INHBE Obesity Creates a Platform Re-rating Catalyst
**Bull thesis:** ARO-INHBE's EASL 2026 data showing ~2x weight loss vs. tirzepatide alone when co-administered is a potential blockbuster signal. The obesity market is the fastest-growing drug market globally ($40B+). If INHBE works as a GLP-1 potentiator, it could be partnered for $1B+ upfront (analogous to the Sarepta deal scale) OR become ARWR's own blockbuster. The bull camp argues this asset is underappreciated and could trigger a re-rating of the platform at a multiple more like a dual-platform biotech (RNAi + metabolic disease).

**Supporting evidence:**
- Phase 1/2a data at EASL 2026: ~-9.4% weight loss at Week 16 (combo with tirzepatide) vs. ~-4.8% tirzepatide alone
- INHBE is genetically validated: INHBE loss-of-function carriers have reduced body mass and fat — strong biological rationale
- No RNAi competitor has a validated obesity asset in clinical trials
- Novo Nordisk (GLP-1 leader) is a natural partner — could pay large upfront for combo strategy [S3]

##### Bull Argument 3: TRiM Platform at Alnylam-Equivalent Value with Greater Optionality
**Bull thesis:** At $10.4B market cap vs. Alnylam at $25B+, Arrowhead trades at a significant discount despite having 20+ clinical programs, one approved product, six Phase 3 programs, and arguably the broadest non-hepatic RNAi pipeline in the industry. If ARWR reaches $3B in annual revenue by 2030 (plozasiran FCS+sHTG + fazirsiran + zodasiran + deal milestones), the stock should trade at 8–10x revenue = $24–30B+ market cap — 2.3x–2.9x upside from current.

**Supporting evidence:**
- Alnylam trades at ~8x FY2026E revenue ($25B MC / ~$3.2B FY2026E rev)
- ARWR at $10.4B trades at ~21x FY2026E revenue ($444M est.) — appears expensive, but the revenue estimate is depressed; FY2030 revenue potential is $2–3B
- Big Pharma has valued Arrowhead's pipeline at >$12B in total deal economics (Sarepta $10B+ + Novartis large + Takeda large + GSK large + Amgen olpasiran milestones) — confirming external pipeline value validation [S1]

---

#### 3. Bear Case — Core Arguments

##### Bear Argument 1: sHTG Phase 3 Failure Would Devastate the Stock
**Bear thesis:** The stock at $73.86 reflects significant optimism about plozasiran sHTG approval. If Phase 3 data disappoints — either primary endpoint miss or unacceptable safety signal — the stock could fall 40–60% (to $30–45). The FCS-only commercial story is too small (~$100–300M peak revenue) to justify a $10.4B enterprise value. The sHTG bet is binary and the outcome is uncertain.

**Supporting evidence:**
- Phase 3 always has ~30–35% failure probability regardless of Phase 2 success (industry base rate)
- The sHTG patient population is heterogeneous — different underlying metabolic drivers could dilute the ApoC-III knockdown efficacy
- Competing therapies (fibrates, omega-3s) are cheap and widely used — payers may demand large discounts even if REDEMPLO is approved for sHTG
- The $46 bear case price target (from the analyst community) implies ~38% downside from current [S4]

##### Bear Argument 2: Governance Concerns Signal Misalignment
**Bear thesis:** The say-on-pay failure (59% against management), combined with ~$37–40M in insider selling over 12 months, and the new equity plan adding 10.5M shares (7.5% dilution) are all signs that management incentives are not aligned with shareholders. If governance activism escalates (ISS campaign, activist investor), management distraction could delay clinical programs or lead to a governance overhaul at a critical juncture (2026 Phase 3 readouts).

**Supporting evidence:**
- Say-on-pay failures at 59% are rare and typically precede either compensation redesign or activist involvement
- CEO/Chair duality is a structural governance weakness
- New CFO selling within months of joining is unusual
- The existing equity plan already authorizes shares that could dilute existing holders by 10%+ [S2]

##### Bear Argument 3: Balance Sheet Leverage and Burn Rate Create Dilution Risk
**Bear thesis:** ARWR has $1.37B in debt, an estimated ~$860–890M annual burn rate, and ~$787M in estimated liquid assets. Without a new deal in FY2027, the company will need to raise capital again — likely through equity at some price. Given the stock has already re-rated 5x from the trough, any new equity raise at $60–75 would be highly dilutive on a per-share basis. The company could need to dilute shareholders by 20–30% to fund operations through FY2028.

**Supporting evidence:**
- FY2026 consensus revenue ~$444M vs. ~$860–890M annual burn → net cash outflow ~$415–445M in FY2026 if no new deals
- Q2 FY2026 positive OCF ($84.4M) was partly driven by deal milestones; underlying product revenue cannot cover the burn
- Total debt at $1,373M creates ~$55–72M/year in cash interest payments
- Oct 2023 equity raise at $28.50 shows management will dilute shareholders when needed [S1]

---

#### 4. Bull Case — 3 Bullets

1. **sHTG Phase 3 success unlocks a $1.5–4B peak revenue opportunity** — REDEMPLO in severe hypertriglyceridemia (600,000 US patients) would be the first FDA-approved drug for this indication; Phase 3 data in Q3 2026 is the defining binary; plozasiran's FCS efficacy (-80% TG) supports high conviction in Phase 3 outcome.

2. **ARO-INHBE obesity/MASH data is an underappreciated platform optionality** — EASL 2026 Phase 1/2a showing ~2x weight loss improvement vs. tirzepatide alone positions ARWR as a GLP-1 potentiator with no RNAi competitor; a partnership deal analogous to Sarepta ($1B+ upfront) is plausible and not priced in.

3. **TRiM platform is valued at a material discount to Alnylam despite comparable pipeline breadth** — ARWR's 20+ programs and 6 Phase 3 assets, with $12B+ in validated partnership economics, represent Alnylam-equivalent pipeline depth at a 60%+ discount to Alnylam's market cap; successful Phase 3 readouts in 2026–2028 should close this gap.

---

#### 5. Bear Case — 3 Bullets

1. **sHTG Phase 3 failure would collapse the commercial thesis** — ~$8B+ of the $10.4B market cap is pipeline optionality beyond FCS; a Phase 3 miss in sHTG (30-35% probability) removes the largest near-term revenue opportunity and could send the stock back to the $30–45 range.

2. **Governance and insider selling signal management-shareholder misalignment** — Say-on-pay failure (59% against), CEO/Chairman duality, $37–40M of insider selling in 12 months, and new equity plan adding 7.5% dilution collectively create a governance risk that could escalate at the worst possible time (during critical 2026 Phase 3 readouts).

3. **Leverage + burn rate creates a dilution trap** — At ~$860–890M annual burn rate vs. ~$444M FY2026E revenue, the company faces a structural cash deficit that requires new deals or equity raises annually; with $1.37B in debt and $787M in liquid assets, the runway is ~3.5 years but only if deal flow materializes; failure to close new partnerships in FY2027 triggers a dilutive equity raise.

---

#### 6. Source Index

[S1] StockAnalysis + XBRL Financial Summary — ARWR_financials/
[S2] Governance/Proxy — ARWR_financials/proxy/
[S3] Investor Presentation — ARWR_financials/presentations/
[S4] Consensus & Market Data — ARWR_financials/other/consensus.md

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/arwr
- Full research API: GET /api/v1/research/ARWR/memo
- Coverage universe: /stocks